Data were analyzed among 473 children. A majority (64.5%) recovered within 12 months, while 35.5% developed chronic ITP. Fourteen (2.96%) children subsequently developed SLE during a mean follow-up of ...

While immune thrombocytopenia (ITP) can occur in both adults and children, what makes pediatric ITP most distinct from adult ITP is the high rate of children who improve on their own, noted James ...

Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

“Doptelet represents a significant advancement in the treatment of children and adolescents with persistent or chronic ITP,” said Rachael Grace, MD, MMSc, Pediatric Hematologist and Director, ...

In this retrospective analysis, responses persisted with hydroxychloroquine treatment. Results of a study suggest treatment using hydroxychloroquine (HCQ) for immune thrombocytopenia (ITP) related to ...

The US Food and Drug Administration (FDA) has approved Novartis' Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an ...

Immune thrombocytopenic purpura (ITP) is characterized by reduced platelet count secondary to immune-mediated destruction, this results in an increased bleeding risk. Autoantibodies binding to ...

Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in ...